ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Metastatic Breast Cancer · HER2 Low Breast Carcinoma · HER2-negative Breast Cancer · Breast Cancer · Breast Cancer Female

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Kristina Fanucci, MD) · kristina_fanucci@dfci.harvard.edu · 617-362-3800
Contact: Principal Investigator (Kristina Fanucci, MD)

Study leads

Kristina Fanucci, MD
Principal Investigator
Dana-Farber Cancer Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence

Breast · Breast Cancer · Pathology

Abroad (travel likely)Recruiting

Hangzhou, China

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Oligometastatic Breast Carcinoma · Breast Cancer · Metastatic Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

La Jolla, United States

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Berlin, Germany · Bremen, Germany